IDYA•benzinga•
FDA Grants Orphan Drug Designation For IDEAYA's Darovasertib For Uveal Melanoma
Summary
The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ: IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 2, 2022 by benzinga